Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%

Abstract Aims Heart failure is a chronic progressive condition, with considerable burden on patients' quality of life and economic burden for the healthcare systems. Before the approval of empagliflozin, there were no proven effective treatments for patients with heart failure with left ventricular...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Spyros Kolovos, Leana Bellanca, Harinala Groyer, Giuseppe M.C. Rosano, Alexandra Solé, Jennifer Gaultney, Stephan Linden
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Oxford University Press 2023-12-01
Schriftenreihe:	ESC Heart Failure
Schlagworte:	Heart failure with left ventricular ejection fraction (HF LVEF) > 40% Heart failure with preserved ejection fraction Cost‐effectiveness Economic evaluation Empagliflozin SGLT2i
Online-Zugang:	https://doi.org/10.1002/ehf2.14470
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!